Research Radartracking 1,138 published studies · 277 human · 6 safety signals · 42 clinical trials · 44 cancer pages · updated Jul 2026Open the Research Map →

Uterine Carcinosarcoma

Uterine Carcinosarcoma: treatment map

Standard care plus compounds studied in the literature, organized by clinical readiness.

Educational only. This is not medical advice and not a recommendation. Confirm anything here with your oncology team.

Treatment map: Uterine Carcinosarcoma

Standard care plus every compound studied in the literature (each cited) and graded by evidence, organized by clinical readiness. A category, not a verdict that anything works — confirm anything here with your oncology team.

125
Interventions
0
Standard of care
28
Tested in people
2
Lab / animal
95
Named in lit.
7
Classes
Standard of care (0) Guideline option (0) Tested in people (28) Lab / animal only (2) Named in the literature (95)

Tested in people, by trial phase: Phase III ×8 · Phase II ×4 · phase not reported ×16

Clinical evidence
Preclinical evidence
Standard of care
Guideline option
Tested in people
Lab / animal only
Named in the literature
Surgery & procedures
2
18
Radiotherapy
2
16
Chemotherapy
11
22
Targeted therapy
6
2
25
Immunotherapy
7
Hormonal therapy
3
Other
4
7

Columns group into clinical evidence (used in, or tested on, people) and preclinical evidence (lab/animal, or only named in the literature). Cell = number of interventions; a dashed cell means none recorded there.

Investigational & adjunct compounds — detail (125)
Phase II trial (4)
anastrozoleoff-labelceralasertibtrabectedin· Recurrent or later-linetrabectedin
Meta-analysis (10)
adjuvant multimodal treatment· Adjuvant (after surgery)chemoradiation· Adjuvant (after surgery)chemotherapy· Adjuvant (after surgery)HER2· biomarker-selectedheterologous component· Recurrent or later-lineminimally invasive surgeryMSI/MMRd· biomarker-selectedNSMPPOLEmut· Recurrent or later-lineradiotherapy· Adjuvant (after surgery)
Named in the literature
adjuvant chemotherapy· Adjuvant (after surgery)adriamycin (doxorubicin)anthracyclinecarboplatin and paclitaxel· First-line (advanced disease)carboplatin/ifosfamide/mesnacarboplatin/paclitaxel· First-line (advanced disease)carboplatin + paclitaxelcarboplatin/paclitaxel/cisplatin/doxorubicin/epirubicincarboplatin plus paclitaxel· Adjuvant (after surgery) · biomarker-selectedcarboplatin plus paclitaxel· Adjuvant (after surgery)carboplatin and paclitaxel· Adjuvant (after surgery)chemotherapeutic combinationscisplatinoff-label· Adjuvant (after surgery)cisplatin/ifosfamide· Adjuvant (after surgery)doxorubicinoff-label· Recurrent or later-linepaclitaxel and platinum· Recurrent or later-linepaclitaxel, ifosfamide, and cisplatin· Adjuvant (after surgery)palliative chemotherapyplatinum· Adjuvant (after surgery)postoperative chemotherapy· Adjuvant (after surgery)taxane/platinum doublet· Recurrent or later-linetopotecanoff-label· Recurrent or later-linedostarlimaboff-label· MaintenanceIL-13Rα2-targeted CAR macrophageslenvatinib plus pembrolizumabPD-L1pembrolizumaboff-labelpembrolizumab + lenvatinib· Recurrent or later-linePRAME?· Adjuvant (after surgery)adjuvant treatment· Adjuvant (after surgery)chemoradiotherapycombined chemo-radiotherapeutic approachNUCB2radiotherapy and chemotherapy· Adjuvant (after surgery)URI1 amplification· Adjuvant (after surgery)aspiration thrombectomyfine-needle aspiration (aspiration cytology)· Recurrent or later-linehysterectomy with bilateral salpingo-oophorectomy and lymphadenectomylymphadenectomymodified radical hysterectomypara-aortic lymphadenectomypartial (subtotal) surgical resectionpelvic lymphadenectomysentinel lymph node biopsysequence-based diagnosticssubtotal hysterectomy and left salpingo-oophorectomysurgery· First-line (advanced disease)surgery (hysterectomy / cytoreduction)surgical resection / debulkingtotal abdominal hysterectomy with bilateral salpingo-oophorectomyconcurrent chemoradiotherapy· Adjuvant (after surgery)cuff brachytherapy· Adjuvant (after surgery)external beam irradiation / vaginal brachytherapy / systemic chemotherapyexternal beam pelvic radiation therapy and HDR brachytherapyexternal beam radiotherapy and chemotherapyexternal radiotherapygamma knife radiationpelvic external beam radiotherapy· Adjuvant (after surgery)pelvic radiation· Adjuvant (after surgery)radiation· Adjuvant (after surgery)radiation and chemotherapyradiochemotherapy· Adjuvant (after surgery)stereotactic radiosurgeryvaginal brachytherapy· Adjuvant (after surgery)whole brain radiotherapywhole-pelvic irradiation· Recurrent or later-lineadagrasibadavosertib· Recurrent or later-linealrizomadlinanti-VEGF / anti-PD-ECGF / anti-PDGFR-β therapy· Recurrent or later-lineaurora kinase inhibitorsavutometinibchemotherapeutic agents with molecular-targeted agentscobimetinibcopanlisibCOX-2fascinFolate receptor alpha· biomarker-selectedgalunisertibhistone deacetylase inhibitors (HDACi)LY2109761LY2157299MRTX1133olapariboff-label· Maintenance · biomarker-selectedPARP inhibitors· biomarker-selectedpazopanib· Recurrent or later-lineSLC1A5SYKtrastuzumab· Recurrent or later-line · biomarker-selectedVEGFPTC-02818F-FDG PET/CTMRI (including DWI and MRS)Transvaginal sonography (TVS)
Lab / animal only

"Tested in people" rows show the highest trial phase found in that compound's cited human studies (Phase I–IV; "phase not reported" = a human study with no phase tag). "Studied" = named in the cited literature for this cancer. "FDA ✓" = FDA-approved for this cancer; "off-label" = an FDA-approved drug used outside its approved indications (per openFDA). Not a claim that anything works.